Cytokinetics (CYTK) Misses Q3 EPS by 35c

Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.16 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
• SanDisk upgraded at JPMorgan after investor day; shares climb